Shree Ganesh Remedies Ltd540737Corporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data
₹657.55
MCap ₹855 Cr · P/E 55.4
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹14 Cr
Sales · Jun 2026
-41.8% YoY
₹3 Cr
Operating Profit · Jun 2026
-54.1% YoY
23.3%
OPM % · Jun 2026
-21.3% YoY
₹1 Cr
Net Profit · Jun 2026
-67.5% YoY
₹0.87
EPS · Jun 2026
-67.7% YoY

📝 Shree Ganesh Remedies Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Shree Ganesh Remedies Ltd reported revenue of ₹14 crore for the quarter ended June 2026 (Q1 FY27), down 41.8% from ₹25 crore in the same quarter last year, and down 56.7% sequentially over the March 2026 quarter.

Net profit fell 67.5% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.87.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 23.3%, compared with 29.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Shree Ganesh Remedies Ltd posted revenue of ₹109 crore, a growth of 0.7% over FY25, with a net profit of ₹18 crore (down 23.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹99 crore with a net profit of ₹15 crore.

Valuation snapshot

At the current price of ₹657.55, 540737 has a market capitalisation of ₹855 crore and a trailing P/E of about 55.4.

Within the Pharmaceuticals industry, it is the 10th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 72.83%, foreign institutional investors (FIIs) 0.00%, public shareholders 27.16% of Shree Ganesh Remedies Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹855 Cr
Current Price ?
₹657.5
P/E ?
55.36above ind
Industry P/E ?
22.40
P/B ?
5.24
P/S ?
8.64
P/FCF ?
N/A
Enterprise Value ?
₹886 Cr
EV/EBITDA ?
28.50
PEG ?
N/A
Earnings Yield ?
2.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹99 Cr
OPM ?
31.4%
Profit after tax (TTM) ?
₹15 Cr
EPS (TTM) ?
₹11.88
ROCE ?
15.0%
ROE ?
9.5%
ROA ?
7.4%
Growth
Sales — latest qtr ?
₹14 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
-41.8%
YoY qtr profit growth ?
-67.5%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
17%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
13%
Financial Health
Debt ?
₹31 Cr
Debt to Equity ?
0.19
Interest Coverage ?
6.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.83%
Change in promoter holding ?
0.03%
Pledged percentage ?
N/A
Market
Return 3 months ?
12.0%
Return 6 months ?
35.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2020Jun 2021Sep 2021Dec 2021Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1313172137253227242530213314 -41.8% -56.7%
Operating Profit 33461781110107107113 -54.1% -70.6%
Other Income 11011101211111 +42.4% -7.8%
Interest 00000000111110 -66.0% -63.6%
Depreciation 01112223223332 +0.8% -12.9%
Profit Before Tax 334616698957492 -66.7% -82.5%
Net Profit 323413565735361 -67.5% -82.1%
EPS 2.161.832.363.289.843.624.994.225.132.693.862.414.880.87 -67.7% -82.2%
OPM % 24.0% 24.1% 26.2% 27.3% 45.4% 32.8% 35.0% 36.6% 40.4% 29.6% 31.7% 31.9% 34.3% 23.3% -21.3% -32.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹109 Cr ₹109 Cr ₹99 Cr +0.7%
Operating Profit ₹39 Cr ₹35 Cr ₹31 Cr -10.7%
OPM % 36.13% 32.05% 31.40% -11.3%
NPM % 21.25% 16.26% 15.60% -23.5%
Other Income ₹4 Cr ₹3 Cr ₹3 Cr -18.8%
Depreciation ₹10 Cr ₹10 Cr ₹10 Cr +9.6%
Interest ₹2 Cr ₹4 Cr ₹3 Cr +68.4%
EBIT ₹30 Cr ₹25 Cr ₹21 Cr -17.3%
PBT ₹31 Cr ₹24 Cr ₹21 Cr -23.2%
Tax — — — —
Net Profit ₹23 Cr ₹18 Cr ₹15 Cr -23.0%
EPS ₹17.96 ₹13.84 ₹12.02 -22.9%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2020Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 9131313 +0.0%
Reserves 33109132150 +13.6%
Borrowings 4363831 -18.4%
Other Liabilities 912814 +75.0%
Total Liabilities 55171192208 +8.3%
Fixed Assets 208195105 +10.5%
CWIP 017912 +33.3%
Investments 351813 -27.8%
Other Assets 32697078 +11.4%
Total Assets 55171192208 +8.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2021Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 330310 -100.0%
Cash from Investing Activity -1-33-350 +100.0%
Cash from Financing Activity -110-10 +100.0%
Net Cash Flow 27-60 +100.0%
Free Cash Flow 3-170 -100.0%
CFO/OP 24%92%104%0% -100.0%

➗ Ratios (latest 4 periods)

Metric Mar 2020Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1015975109 +45.3%
Inventory Days 61156223209 -6.3%
Days Payable 43516182 +34.4%
Cash Conversion Cycle 119164238236 -0.8%
Working Capital Days 10389111169 +52.3%
ROCE % 35%—19%15% -21.1%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 72.80%72.80%72.80%72.83% +0.0%
FIIs 0.01%0.01%0.00%0.00% —
Public 27.20%27.19%27.20%27.16% -0.1%
No. of Shareholders 9,1668,7528,4428,058 -4.5%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Shree Ganesh Remedies Ltd's revenue in Q1 FY27?
Shree Ganesh Remedies Ltd reported revenue of ₹14 crore for the quarter ended June 2026 (Q1 FY27), down 41.8% from ₹25 crore in the same quarter last year, and down 56.7% sequentially over the March 2026 quarter.
What was Shree Ganesh Remedies Ltd's net profit in Q1 FY27?
Net profit fell 67.5% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.87.
What is 540737's market capitalisation and P/E ratio?
At the current price of ₹657.55, 540737 has a market capitalisation of ₹855 crore and a trailing P/E of about 55.4.
Who owns Shree Ganesh Remedies Ltd? (shareholding pattern)
As of Mar 2026, promoters held 72.83%, foreign institutional investors (FIIs) 0.00%, public shareholders 27.16% of Shree Ganesh Remedies Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI